BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 21388296)

  • 1. Epidemiology and clinical features of community-onset bacteremia caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae.
    Lee JA; Kang CI; Joo EJ; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Ko KS; Lee NY; Song JH
    Microb Drug Resist; 2011 Jun; 17(2):267-73. PubMed ID: 21388296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study.
    Mosqueda-Gómez JL; Montaño-Loza A; Rolón AL; Cervantes C; Bobadilla-del-Valle JM; Silva-Sánchez J; Garza-Ramos U; Villasís-Keever A; Galindo-Fraga A; Palacios GM; Ponce-de-León A; Sifuentes-Osornio J
    Int J Infect Dis; 2008 Nov; 12(6):653-9. PubMed ID: 18511321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and molecular epidemiology of healthcare-associated infections due to extended-spectrum beta-lactamase (ESBL)-producing strains of Escherichia coli and Klebsiella pneumoniae that harbor multiple ESBL genes.
    Apisarnthanarak A; Kiratisin P; Mundy LM
    Infect Control Hosp Epidemiol; 2008 Nov; 29(11):1026-34. PubMed ID: 18947321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for multidrug resistance in nosocomial bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Park SY; Kang CI; Joo EJ; Ha YE; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
    Microb Drug Resist; 2012 Oct; 18(5):518-24. PubMed ID: 22742454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-beta-lactamase-producing Klebsiella pneumoniae.
    Pai H; Kang CI; Byeon JH; Lee KD; Park WB; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3720-8. PubMed ID: 15388426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High clonal diversity in a non-outbreak situation of clinical ESBL-producing Klebsiella pneumoniae isolates in the first national surveillance program in Cuba.
    Quiñones D; Valverde A; Rodríguez-Baños M; Kobayashi N; Zayaz A; Abreu M; Cantón R; del Campo R
    Microb Drug Resist; 2014 Feb; 20(1):45-51. PubMed ID: 23692050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
    Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
    Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome.
    Tumbarello M; Spanu T; Sanguinetti M; Citton R; Montuori E; Leone F; Fadda G; Cauda R
    Antimicrob Agents Chemother; 2006 Feb; 50(2):498-504. PubMed ID: 16436702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
    Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
    Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging extended-spectrum β-lactamase-producing Klebsiella pneumoniae causing community-onset urinary tract infections: a case-control-control study.
    Boix-Palop L; Xercavins M; Badía C; Obradors M; Riera M; Freixas N; Pérez J; Rodríguez-Carballeira M; Garau J; Calbo E
    Int J Antimicrob Agents; 2017 Aug; 50(2):197-202. PubMed ID: 28552471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mortality risk factors for bloodstream infections caused by extended-spectrum beta-lactamase-producing microorganisms].
    Ferrández O; Grau S; Saballs P; Luque S; Terradas R; Salas E
    Rev Clin Esp; 2011 Mar; 211(3):119-26. PubMed ID: 21371702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective study of an outbreak in a Kuwaiti hospital of multidrug-resistant Klebsiella pneumoniae possessing the new SHV-112 extended-spectrum beta-lactamase.
    Dashti AA; Jadaon MM; Amyes SG
    J Chemother; 2010 Oct; 22(5):335-8. PubMed ID: 21123157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae hospital acquired bacteremia. Risk factors and clinical outcome.
    Panhotra BR; Saxena AK; Al-Ghamdi AM
    Saudi Med J; 2004 Dec; 25(12):1871-6. PubMed ID: 15711657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.
    Denisuik AJ; Lagacé-Wiens PR; Pitout JD; Mulvey MR; Simner PJ; Tailor F; Karlowsky JA; Hoban DJ; Adam HJ; Zhanel GG;
    J Antimicrob Chemother; 2013 May; 68 Suppl 1():i57-65. PubMed ID: 23587779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Prevalence of Hypervirulent Klebsiella pneumoniae Infection in China: Geographic Distribution, Clinical Characteristics, and Antimicrobial Resistance.
    Zhang Y; Zhao C; Wang Q; Wang X; Chen H; Li H; Zhang F; Li S; Wang R; Wang H
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6115-20. PubMed ID: 27480857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence.
    Marra AR; Wey SB; Castelo A; Gales AC; Cal RG; Filho JR; Edmond MB; Pereira CA
    BMC Infect Dis; 2006 Feb; 6():24. PubMed ID: 16478537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of extended-spectrum β-lactamase-producing escherichia coli as a cause of community-onset bacteremia in South Korea: risk factors and clinical outcomes.
    Park SH; Choi SM; Lee DG; Kim J; Choi JH; Kim SH; Kwon JC; Yoo JH
    Microb Drug Resist; 2011 Dec; 17(4):537-44. PubMed ID: 21875342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
    Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors and outcomes for bloodstream infections with extended-spectrum beta -lactamase-producing Klebsiella pneumoniae ; Findings of the nosocomial surveillance system in Hungary.
    Szilágyi E; Füzi M; Böröcz K; Kurcz A; Tóth A; Nagy K
    Acta Microbiol Immunol Hung; 2009 Sep; 56(3):251-62. PubMed ID: 19789140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.